দেশ: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
Isoxsuprine hydrochloride (UNII: V74TEQ36CO) (Isoxsuprine - UNII:R15UI3245N)
Vista Pharmaceuticals, Inc.
ORAL
PRESCRIPTION DRUG
Based on a review of this drug by the National Academy of Sciences -National Research Council and / or other information, the FDA has classified the medications as follows : Possibly Effective : 1. For the relief of symptoms associated with cerebral vascular insufficiency 2. In Peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. Oral There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
Isoxsuprine HCI tablets, USP are supplied in HDPE bottles. 20 mg Bottles of 1,000's: NDC61971-065-10 Manufactured in India by Vista Pharmaceuticals, Limited. For Vista Pharmaceuticals, Inc. Revised:07/2017
unapproved drug other
ISOXSUPRINE HYDROCHLORIDE- ISOXSUPRINE HYDROCHLORIDE TABLET VISTA PHARMACEUTICALS, INC. _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA. For further information about unapproved drugs, click here._ ---------- ISOXSUPRINEHYDROCHLORIDE TABLETS, USP _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA._ CAUTION: Federal Law prohibits dispensing without prescription DESCRIPTION Isoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter taste, It has a following structural formula INDICATIONS Based on a review of this drug by the National Academy of Sciences -National Research Council and / or other information, the FDA has classified the medications as follows : Possibly Effective : 1. For the relief of symptoms associated with cerebral vascular insufficiency 2. In Peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. COMPOSITION Each tablet contains lsoxsuprine HCI 20 mg. These tablets contain the following inactive ingredients: dibasic calcium phosphate (anhydrous), lactose, magnesium stearate. microcrystalline cellulose, povidone k30, and sodium starch glycolate. DOSAGEANDADMINISTRATION Oral:10 to 20 mg three or four times daily CONTRAINDICATIONS AND CAUTIONS ORAL There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding. ADVERSE REACTIONS On rare occasion, oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued. Although available evidence suggests a temporal association of these reactions with সম্পূর্ণ নথি পড়ুন